Human monoclonal antibodies against CD20

Details Human monoclonal antibodies against CD20 Human monoclonal antibodies against CD20

2005-04-20

2010-12-14

Gussow, Anne M. (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S131100, C424S133100, C424S135100, C424S141100, C424S178100, C435S007100, C435S007210, C435S007230, C435S007240, C530S387100, C530S387200, C530S387300, C530S388100, C530S388700, C530S391100, C530S391300, C530S391700

Reexamination Certificate

active

07850962

ABSTRACT:
Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

REFERENCES:
patent: 5182368 (1993-01-01), Ledbetter et al.
patent: 5247069 (1993-09-01), Ledbetter et al.
patent: 5506126 (1996-04-01), Seed et al.
patent: 5540926 (1996-07-01), Aruffo et al.
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5681722 (1997-10-01), Newman et al.
patent: 5693780 (1997-12-01), Newman et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5750105 (1998-05-01), Newman et al.
patent: 5756096 (1998-05-01), Newman et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5776456 (1998-07-01), Anderson et al.
patent: 5786456 (1998-07-01), Ledbetter et al.
patent: 5830731 (1998-11-01), Seed et al.
patent: 5843398 (1998-12-01), Kaminski et al.
patent: 5843439 (1998-12-01), Anderson et al.
patent: 5849898 (1998-12-01), Seed et al.
patent: 5945513 (1999-08-01), Aruffo et al.
patent: 6015542 (2000-01-01), Kaminski et al.
patent: 6090365 (2000-07-01), Kaminski et al.
patent: 6111093 (2000-08-01), Seed et al.
patent: 6120767 (2000-09-01), Robinson et al.
patent: 6136310 (2000-10-01), Hanna et al.
patent: 6183744 (2001-02-01), Goldenberg
patent: 6218525 (2001-04-01), Seed et al.
patent: 6224866 (2001-05-01), Barbera-Guillem
patent: 6287537 (2001-09-01), Kaminski et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 6395676 (2002-05-01), Blum et al.
patent: 6399061 (2002-06-01), Anderson et al.
patent: 6455043 (2002-09-01), Grillo-López
patent: 6696550 (2004-02-01), LaRosa et al.
patent: 6846476 (2005-01-01), White
patent: 6849425 (2005-02-01), Huse et al.
patent: 6896885 (2005-05-01), Hanna
patent: 7378503 (2008-05-01), Graus et al.
patent: 2001/0018041 (2001-08-01), Hanna et al.
patent: 2001/0033839 (2001-10-01), Barbera-Guillem
patent: 2001/0056066 (2001-12-01), Bugelski et al.
patent: 2002/0006404 (2002-01-01), Hanna et al.
patent: 2002/0009427 (2002-01-01), Wolin et al.
patent: 2002/0009444 (2002-01-01), Grillo-López
patent: 2002/0012665 (2002-01-01), Hanna
patent: 2002/0028178 (2002-03-01), Hanna et al.
patent: 2002/0039557 (2002-04-01), White
patent: 2002/0041847 (2002-04-01), Goldenberg
patent: 2002/0048550 (2002-04-01), Vallera et al.
patent: 2002/0058029 (2002-05-01), Hanna
patent: 2002/0064823 (2002-05-01), Welcher et al.
patent: 2002/0071807 (2002-06-01), Goldenberg
patent: 2002/0128448 (2002-09-01), Reff
patent: 2002/0150580 (2002-10-01), Newman et al.
patent: 2002/0159996 (2002-10-01), Hariharan et al.
patent: 2004/0167319 (2004-08-01), Teeling et al.
patent: WO 88/04936 (1988-07-01), None
patent: WO 92/03918 (1992-03-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 94/11026 (1994-05-01), None
patent: WO 94/25585 (1994-11-01), None
patent: WO 97/09351 (1997-03-01), None
patent: WO 98/04281 (1998-02-01), None
patent: WO 98/24884 (1998-06-01), None
patent: WO 98/42378 (1998-10-01), None
patent: WO 99/14353 (1999-03-01), None
patent: WO 99/33485 (1999-07-01), None
patent: WO 00/03733 (2000-01-01), None
patent: WO 00/09160 (2000-02-01), None
patent: WO 00/20864 (2000-04-01), None
patent: WO 00/27428 (2000-05-01), None
patent: WO 00/27433 (2000-05-01), None
patent: WO 00/67796 (2000-11-01), None
patent: WO 00/74718 (2000-12-01), None
patent: WO 01/03734 (2001-01-01), None
patent: WO 01/10460 (2001-02-01), None
patent: WO 01/10462 (2001-02-01), None
patent: WO 01/34194 (2001-05-01), None
patent: WO 01/72333 (2001-10-01), None
patent: WO 01/74388 (2001-10-01), None
patent: WO 01/80884 (2001-11-01), None
patent: WO 01/97843 (2001-12-01), None
patent: WO 01/97858 (2001-12-01), None
patent: WO 02/04021 (2002-01-01), None
patent: WO 02/07783 (2002-01-01), None
patent: WO 02/12437 (2002-02-01), None
patent: WO 02/22212 (2002-03-01), None
patent: WO 02/34790 (2002-05-01), None
patent: WO 02/060484 (2002-08-01), None
patent: WO 02/060485 (2002-08-01), None
patent: WO 02/062946 (2002-08-01), None
patent: WO 2004/035607 (2004-04-01), None
Rudikoff, Giusti, Cook, and Scharff. Single amino acid substitution altering antigen binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
Mac Callum, Martin, and Thornton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of abbreviated complementarity determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanzied monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Chen, Wiesmann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecule Biology, 1999. vol. 294, pp. 151-162.
Granziero, Krajewski, Farness, Yuan, Courtney, Jackson, Peterson, and Vitiello. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. European Journal of Immunology, 1999. vol. 29, pp. 1127-1138.
Byers. What can randomized controlled trials tell us about nutrition and cancer prevention? CA Cancer Journal Clin. 1999. vol. 49, pp. 353-361.
Mount and Gilliland. Emerging biological therapies in systemic lupus erythematosus. Clinical Pharmacology and Therapeutics, 2008. vol. 83, pp. 167-171.
Perosa, Prete, Racanelli, and Dammacco. CD20 depleting therapy in autoimmune diseases: from basic research to the clinic. Journal of Internal Medicine, 2010. vol. 267, pp. 260-277.
Johns, Doyle, Lipman, Cwynarski, Cleverly, Isaacson, Shaw, and Agarwal. Successful treatment of HIV-associated multicentric Castleman's disease and multiple organ failure with rituximab and supportive care: a case report. Journal of Medical Care Reports, 2010. vol. 4:32 (pp. 1-6).
Edwards, J. C. W. And Cambridge, G., “Sustained Improvement in Rheumatoid Arthritis Following a Protocol Designed to Deplete B Lymphocytes,”Rheumatology, 40:205-211 (2001).
Gazzano-Santoro, H., et al., “A Non-Radioactive Complement-Dependent Cytotoxicity Assay for Anti-CD20 Monoclonal Antibody ,”Journal of Immunological Methods, 202:163-171 (1997).
van Spriel, A. B., et al., “Immunotherapeutic Perspective for Bispecific Antibodies,”Immunology Today, 21(8):391-397 (2000).
Supplemental European Search Report for EP 03609145.0 (PCT/US03/33057).
International Search Report for PCT/US03/33057.
Dechant, M., et al., “Novel Fully Human CD20 Antibodies with Different Mechanisms of Action.” Blood, vol. 102, No. 11, p. 103a (Nov. 2003).
Teeling, J.L., et al., “Characterization of New Human CD20 Monoclonal Antibodies with Potent Cytolytic Activity Against Non-Hodgkin Lymphomas,” Blood, W.B. Saunders Company, Orlando, FL., US, vol. 104, No. 6, pp. 1793-1800 (Sep. 2004).
Coiffier, B., “Monoclonal Antibodies Combined to Chemotherapy for the Treatment of P

Affiliated with

Also associated with

Rating

Human monoclonal antibodies against CD20 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human monoclonal antibodies against CD20, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibodies against CD20 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4221368